BR0011743A - Método para modular a atividade de receptor de fxr - Google Patents

Método para modular a atividade de receptor de fxr

Info

Publication number
BR0011743A
BR0011743A BR0011743-9A BR0011743A BR0011743A BR 0011743 A BR0011743 A BR 0011743A BR 0011743 A BR0011743 A BR 0011743A BR 0011743 A BR0011743 A BR 0011743A
Authority
BR
Brazil
Prior art keywords
fxr receptor
receptor activity
modulate fxr
activity
modulate
Prior art date
Application number
BR0011743-9A
Other languages
English (en)
Inventor
Barry M Forman
Richard L Beard
Roshantha A Chandraratna
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR0011743A publication Critical patent/BR0011743A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: "MéTODOS PARA MODULAR A ATIVIDADE DE RECEPTOR DE FXR". Métodos para modular a atividade de receptor de FXR de mamíferos. Os métodos incluem métodos de tratamento de um mamíferos hiper- ou hipocolesterolêmico compreendendo contatar o mamíferos com compostos sintéticos tendo atividade de receptor de FXR.
BR0011743-9A 1999-06-11 2000-06-09 Método para modular a atividade de receptor de fxr BR0011743A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13896899P 1999-06-11 1999-06-11
PCT/US2000/015912 WO2000076523A1 (en) 1999-06-11 2000-06-09 Methods for modulating fxr receptor activity

Publications (1)

Publication Number Publication Date
BR0011743A true BR0011743A (pt) 2002-03-05

Family

ID=22484498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011743-9A BR0011743A (pt) 1999-06-11 2000-06-09 Método para modular a atividade de receptor de fxr

Country Status (10)

Country Link
EP (1) EP1185277B1 (pt)
JP (1) JP2003501477A (pt)
CN (1) CN1368884A (pt)
AT (1) ATE307595T1 (pt)
AU (1) AU768806B2 (pt)
BR (1) BR0011743A (pt)
CA (1) CA2377320A1 (pt)
DE (1) DE60023493T2 (pt)
HK (1) HK1047705A1 (pt)
WO (1) WO2000076523A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132223A1 (en) * 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
US20020119958A1 (en) * 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
US20030144360A1 (en) * 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
EP1465882B1 (en) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
JP5094384B2 (ja) 2004-03-12 2012-12-12 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒリガンドを使用する線維症の処置
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
CA2732323C (en) 2008-07-30 2017-06-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
JP5535233B2 (ja) 2008-11-19 2014-07-02 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５モジュレーターおよびその使用方法
EP2379081B1 (en) 2008-12-19 2013-03-20 Royal College of Surgeons in Ireland Treatment of diarrhoea
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CA3047776C (en) 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
CN105764569B (zh) 2013-09-11 2019-09-13 国家医疗保健研究所 治疗乙型肝炎病毒感染的方法和药物组合物
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
CN114173784B (zh) 2019-07-18 2023-12-01 埃尼奥制药公司 降低干扰素的副作用的方法
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
FR2707989B1 (fr) * 1993-07-22 1995-10-13 Pf Medicament Nouveaux dérivés de benzylamines silylées, leurs sels, leurs procédés de fabrication et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
HK1047705A1 (zh) 2003-03-07
AU5603200A (en) 2001-01-02
CN1368884A (zh) 2002-09-11
WO2000076523A1 (en) 2000-12-21
DE60023493D1 (de) 2005-12-01
JP2003501477A (ja) 2003-01-14
CA2377320A1 (en) 2000-12-21
EP1185277B1 (en) 2005-10-26
EP1185277A1 (en) 2002-03-13
ATE307595T1 (de) 2005-11-15
DE60023493T2 (de) 2006-07-20
AU768806B2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
BR0011743A (pt) Método para modular a atividade de receptor de fxr
CO4520282A1 (es) Piridinas sustituidas por 2-arilo
ID23183A (id) Perangsangan modulator reseptor asam amino
DK0907631T3 (da) Uorganiske ionreceptoraktive forbindelser
ATE426343T1 (de) Tragerplatte fur nassrasierer
ID20500A (id) Metoda untuk memperoleh asam akrilat
EA200000351A1 (ru) Лечение кондуктивных нарушений
DE59500811D1 (de) Trägerplatte für baugruppen
ES2172027T3 (es) Reduccion del crecimiento del pelo.
EA200000349A1 (ru) Способ лечения оппозиционного расстройства
DE58903736D1 (de) Verfahren zur behandlung von biomassen, z.b. klaerschlaemmen, guelle, usw.
NO20023749D0 (no) Kahalalid-forbindelser
EA199900942A1 (ru) Дисперсии арамидных волокон и арамидное бумажное полотно
DE69732762D1 (de) Indanderivate für antipsychotische mittel
EA199800867A1 (ru) Соединения тетрагидробетакарболина
BR0011741A (pt) Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear
WO2003043581A3 (en) Composition and method for modulating bar/fxr receptor activity
DK0756602T3 (da) CCK- eller gastrin-modulerende 5-heterocyclo-1,5-benzodiazepiner
PT983272E (pt) Nova classe de compostos fotoactivos derivados de benzoporfirina
DE69806198T2 (de) Laservorrichtungen zur Plattentexturierung
DK1007666T3 (da) Neurturinreceptor
DE69808281D1 (de) Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration
PT915988E (pt) Processo para a producao fermentativa de cefalosporinas desaciladas
DE69725577D1 (de) Verwendung von mitteln die den wachstumsfaktor beeinflussen
ATE106724T1 (de) Phosphatbinder zur oralen verabreichung.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN SALES, LLC (US)

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.